Business Context and Reporting Period
Company: EXICURE, INC. (XCUR)
Filing Type: Form 8-K (Current Report)
Date of Report: January 11, 2021
Reporting Period: Single event date (January 11, 2021)
Business Context: The registrant is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. The filing primarily addresses a regulatory milestone regarding its drug candidate, Cavrotolimod (AST-008).
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Milestone: On January 11, 2021, the Company announced it was granted two fast track designations from the U.S. Food and Drug Administration (FDA) for its drug candidate Cavrotolimod (AST-008). This represents a significant development in the company's clinical pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA fast track designations. No specific financial guidance or forward-looking revenue projections are included in this document.
Risks and Contingencies: The filing includes standard disclaimers stating that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. As an emerging growth company, the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the specific indications for which the two FDA fast track designations were granted for Cavrotolimod (AST-008) by reviewing the press release in Exhibit 99.1.
- Confirm the current clinical trial status and next expected milestones for AST-008 following this designation.
- Review the company's most recent 10-K or 10-Q filings for up-to-date financial position, cash runway, and liquidity status, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the regulatory timeline or potential partnership opportunities related to the fast track designation.